Benefits and risk of sodium oxybate in idiopathic hypersomnia versus narcolepsy type 1: a chart review
Authors:
- 1 January 2016
- journal article
- research article
- Published by Elsevier in Sleep Medicine
- Vol. 17, 38-44
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Use of subcutaneous flumazenil preparations for the treatment of idiopathic hypersomnia: A case reportJournal of Psychopharmacology, 2014
- Improvement in daytime sleepiness with clarithromycin in patients with GABA-related hypersomnia: Clinical experienceJournal of Psychopharmacology, 2013
- Pitolisant versus placebo or modafinil in patients with narcolepsy: a double-blind, randomised trialThe Lancet Neurology, 2013
- Mazindol in narcolepsy and idiopathic and symptomatic hypersomnia refractory to stimulants: A long-term chart reviewSleep Medicine, 2013
- Modulation of Vigilance in the Primary Hypersomnias by Endogenous Enhancement of GABAAReceptorsScience Translational Medicine, 2012
- Sodium Oxybate for Narcolepsy with Cataplexy: Systematic Review and Meta-AnalysisJournal of Clinical Sleep Medicine, 2012
- Benefit and risk of modafinil in idiopathic hypersomnia vs. narcolepsy with cataplexySleep Medicine, 2011
- Subjective symptoms in idiopathic hypersomnia: beyond excessive sleepinessJournal of Sleep Research, 2010
- Delayed Onset of Pulmonary Hypertension Associated With an Appetite Suppressant, MazindolJapanese Circulation Journal, 2000
- THE γ-HYDROXYBUTYRATE SIGNALLING SYSTEM IN BRAIN: ORGANIZATION AND FUNCTIONAL IMPLICATIONSProgress in Neurobiology, 1997